Paolo Tarantino, MD

Paolo Tarantino, MD, discusses considerations around the frontline treatment of metastatic HER2-positive breast cancer.

Paolo Tarantino, MD, discusses the evolving role of anthracycline- and taxane-based regimens in HER2-positive breast cancer.

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Paolo Tarantino, MD, discusses updated safety data from the phase 3 DESTINY-Breast03 trial of T-DXd in HER2+ breast cancer.

Paolo Tarantino, MD, discusses updated data from the phase 3 DESTINY-Breast03 trial of trastuzumab deruxtecan in HER2-positive breast cancer.

Paolo Tarantino, MD, and Yan Leyfman, MD, discuss ongoing investigations into the treatment of HR+ breast cancer presented at the 2024 ASCO Annual Meeting.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference

Paolo Tarantino, MD, discusses ongoing investigations into the use of antibody-drug conjugates targeting B7-H4 vedotin, highlighting their potential significance for the treatment paradigm in breast cancer.

Paolo Tarantino, MD, discusses the importance of understanding the role that payloads play in treatment with antibody-drug conjugates in breast cancer.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Paolo Tarantino, MD, discusses the use of antibody drug conjugates in patients with hormone receptor-positive breast cancer.

Paolo Tarantino, MD, discusses typical conversations oncologists should have with patients regarding the platinum chemotherapy shortage, as well as the importance of honest communication about treatment regimen changes.

Paolo Tarantino, MD, discusses how the ongoing shortages of carboplatin and cisplatin in the United States are affecting patients with breast cancer and the importance of overcoming this wave of shortages and preventing this issue from recurring in the future.

Paolo Tarantino, MD, discusses the evolution and impact of the continued investigation of antibody-drug conjugates in the treatment of patients with hormone receptor–positive breast cancer.

Paolo Tarantino, MD, discusses the expansion and selection of effective treatment options for patients with hormone receptor-positive breast cancer who progressed on a CDK 4/6 inhibitor.

Paolo Tarantino, MD, highlights additional abstracts from SABCS 2022 that he found particularly interesting.

Komal Jhaveri, MD, FACP, explains the potential role ADCs may have in the future of breast cancer treatment.

Dr Jhaveri explains her thoughts on sequencing ADCs in the treatment of triple-negative breast cancer.

Drs Jhaveri and Tarantino discuss the standard of practice for managing triple negative breast cancer.

Komal Jhaveri, MD, FACP, discusses the role of capivasertib in ER-positive HER2-negative mBC and the design and outcomes of the CAPItello 291 trial.

Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.

Komal Jhaveri, MD, FACP, explains data on the frontline standard of care treatment approaches for ER-positive HER2-negative mBC.

Paolo Tarantino, MD, provides an overview of ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- mBC), highlighting the prevalence, patient populations, and the typical prognosis.

Paolo Tarantino, MD, discusses the impact of the phase 3 DESTINY-Breast04 trial in the treatment of HER2-low breast cancer.

Paolo Tarantino, MD, researcher, the European Institute of Oncology; clinical research fellow, Dana-Farber Cancer Institute, discusses the options available in the second line for patients with HER2-positive metastatic breast cancer.

Paolo Tarantino, MD, discusses the importance of the phase 3 DESTINY-Breast04 trial in HER2-low breast cancer.